Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System

ConditionsMitral Regurgitation Mitral Valve Disease Mitral Valve Insufficiency Mitral Valve Prolapse Heart Valve Diseases

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorNeoChord

About this trial

The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.

Eligibility criteria

Qualifiers

Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve regurgitation

Study procedure completed after 31 December 2016

Disqualifiers

Heavily calcified valves

Valvular retraction with severely reduced mobility

Active bacterial endocarditis

Complex mechanism of MR (leaflet perforation, etc.)

Trial design

Treatments tested in this trial

NeoChord Artificial Chordae Delivery System, Model DS1000

Treatment groups

No treatment groups listed

Locations

Germany

University of Bonn Bonn Germany

CVC Frankfurt Frankfurt Germany

University of Mainz Mainz Germany

Greece

Hippokration Hospital Athens Greece

Sponsors and collaborators

NeoChord

Lead sponsor

Source ClinicalTrials.gov